Mereo Biopharma Group Plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-9.9%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.03next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly36.2MTarget: Sufficient to fund operations into mid-2027
Quarterly Net Loss Quarterly-6.7MTarget: Narrowing losses through tight resource management
Watch Items
- Regulatory feedback on pediatric path for setrusumab (UX143) in osteogenesis imperfecta (OI)Trigger: Definitive feedback from FDA/EMA on potential approval path based on secondary endpointsAction: Re-evaluate commercialization timeline and pre-commercial investments in Europe
- Alvelestat (MPH-966) Phase 3 partnering discussionsTrigger: Execution of a global or regional partnership transactionAction: Initiate Phase 3 pivotal study in AATD-LD within six months of closing
- Vantictumab (OMP18R5) Phase 2 trial initiation by partner āshibioTrigger: First patient dosed in autosomal dominant osteopetrosis Type 2 (ADO2) trialAction: Monitor clinical progress and prepare for potential European development milestones
Research as of 20 Jun 2026